Cytokinetics (NASDAQ: CYTK) CEO sells 7,500 shares, retains large stake

Rhea-AI Filing Summary

Cytokinetics Inc President & CEO Robert I. Blum sold 7,500 shares of Common Stock in an open-market transaction at $66.63 per share. Following the sale, he directly holds 422,830 shares. In addition, 2,083 shares are held indirectly by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares by The Brittany Blum 2003 Irrevocable Trust.

Insider Trade Summary 10b5-1

Net Seller: 7,500 shares ($499,725)

Net Sell 3 txns

Insider Blum Robert I

Role President & CEO

Sold 7,500 shs ($500K)

Type	Security	Shares	Price	Value
Sale	Common Stock	7,500	$66.63	$500K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 422,830 shares (Direct); Common Stock — 2,083 shares (Indirect, by Trust 1)

Footnotes (1)

1. Shares held by The Bridget Blum 2003 Irrevocable Trust. Shares held by The Brittany Blum 2003 Irrevocable Trust.

Key Figures

Shares sold: 7,500 shares Sale price: $66.63 per share Direct holdings after sale: 422,830 shares +2 more

5 metrics

Shares sold 7,500 shares Open-market sale of Common Stock on 2026-04-01

Sale price $66.63 per share Price for the 7,500 shares sold

Direct holdings after sale 422,830 shares Common Stock directly held by CEO after transaction

Indirect holdings – Trust 1 2,083 shares Common Stock held by The Bridget Blum 2003 Irrevocable Trust

Indirect holdings – Trust 2 2,083 shares Common Stock held by The Brittany Blum 2003 Irrevocable Trust

Key Terms

open-market sale, Common Stock, indirect ownership, Irrevocable Trust

4 terms

open-market sale financial

"transaction_action: "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

"security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

indirect ownership financial

"direct_or_indirect: "I" and nature_of_ownership: "by Trust 1""

Irrevocable Trust financial

"Shares held by The Bridget Blum 2003 Irrevocable Trust."

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Blum Robert I

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/01/2026		S		7,500	D	$66.63	422,830	D
Common Stock								2,083	I	by Trust 1(1)
Common Stock								2,083	I	by Trust 2(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares held by The Bridget Blum 2003 Irrevocable Trust.

2. Shares held by The Brittany Blum 2003 Irrevocable Trust.

	/s/ John O. Faurescu, attorney-in-fact for Mr. Blum	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did CYTOKINETICS (CYTK) CEO Robert Blum report?

Robert I. Blum reported an open-market sale of 7,500 shares of Cytokinetics Common Stock at $66.63 per share. The transaction was recorded as a non-derivative sale and reflects a reduction in his directly held shares while maintaining a substantial remaining position.

How many CYTK shares does the CEO hold after the reported sale?

After selling 7,500 shares, Robert I. Blum directly holds 422,830 shares of Cytokinetics Common Stock. This figure reflects only his direct ownership and does not include additional shares held indirectly through trusts associated with his family.

At what price were the CYTOKINETICS (CYTK) shares sold in this Form 4 filing?

The reported open-market sale was executed at $66.63 per share for Cytokinetics Common Stock. This price applies to all 7,500 shares sold in the transaction disclosed, according to the Form 4 insider filing data provided.

What indirect CYTK share holdings related to CEO Robert Blum are disclosed?

The filing shows 2,083 Cytokinetics shares held by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares held by The Brittany Blum 2003 Irrevocable Trust. These positions are reported as indirect ownership entries associated with Robert I. Blum.

Does this CYTOKINETICS Form 4 include any derivative securities activity?

No derivative securities activity is shown in the provided data. The transaction summary lists zero exercises and a derivative transaction count of zero, indicating only a non-derivative open-market sale of Common Stock was reported for this filing.

What is the overall net share change reported in this CYTK Form 4?

The transaction summary shows a net-sell direction with 7,500 shares sold and no purchases. This results in a net change of negative 7,500 shares for Robert I. Blum’s reported holdings in Cytokinetics Common Stock in this filing.